Business Insider Intelligenceinsitro uses its platform to analyze genetic and clinical data to discover new contenders for drug treatments — and it plans to put the fresh cash toward further developing its AI tech. The San Francisco-based biotech is different from most AI firms in that it produces its own vast amounts of data to train its machine learning technology, rather than leaning on existing data sets that could result in poorly trained platforms, Forbes.
Exscientia's platform uses AI to automate drug discovery and help design novel drug molecules — and it plans on expanding its pipeline and global footprint with its new funding. The UK-based firm facilitates drug discovery by applying its AI to published literature to identify drug targets. It entered its first drug — a treatment for OCD — into clinical trials last year and has landed partnerships with companies like Bristol-Myers Squibb, Bayer, and Scripps Research, for example.
We expect pharma companies to increasingly eye tie ups with AI-focused startups as they race to develop treatments for the coronavirus — but drug makers may not see a quick return on their investments. The coronavirus pandemic has sparked a great deal of
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
स्रोत: Forbes - 🏆 394. / 53 और पढो »
स्रोत: BusinessInsider - 🏆 729. / 51 और पढो »
स्रोत: BusinessInsider - 🏆 729. / 51 और पढो »